DF Group enters blood plasma market

Cologne, 30 April 2025 – The newly founded Deutsche Blutplasma HP GmbH, a wholly owned subsidiary of the intermediate holding company DF Health & Pharma Holding GmbH of DF Deutsche Forfait AG (ISIN: DE000A2AA204) (DF AG), signed a purchase agreement for the assets of the insolvent Ruhr-Plasma-Zentrum Bochum GmbH. DF Group is thus continuing its announced M&A strategy with targeted investments in the food and pharmaceutical sectors and is tapping into an extremely lucrative business segment by entering the field of blood plasma collection.

Human blood plasma is needed in the pharmaceutical industry to produce various vital medicines such as blood coagulants and immunoglobulins. The global market for blood plasma derivatives is estimated to reach a volume of over 50 billion US dollars in 2024. According to the Federal Ministry of Health, around 15,000 blood and plasma donations are needed every day in Germany alone. A person in this country is allowed to donate plasma up to 60 times a year - in return for a legally permissible expense allowance.

‘The Ruhr-Plasma-Zentrum Bochum GmbH has developed into a permanent institution for plasma donors in Bochum over more than 30 years and is centrally located directly at the main railway station - Deutsche Blutsplasma HP GmbH would like to continue this success story,’ explains Management Board member Hans-Joachim von Wartenberg on the occasion of the completed asset deal. ‘The collection of blood plasma is fundamentally a very profitable business, and the company's operating business with a loyal base of stem donors has also developed positively in the past. We will now appoint a new management team that will systematically drive forward the expansion of business activities and, in particular, significantly strengthen marketing, which has been neglected to date.’

With this acquisition, DF Group has successfully completed its second M&A transaction within ten months. The new location in Bochum will serve as a starting point for the further expansion of the blood plasma division. It is conceivable that the company will open its own new stores as well as potentially taking over other locations throughout Germany or in neighbouring countries.

The purchase will take effect on 1 May 2025 and is subject to the approval of the creditors' meeting.

About DF Group

DF Group is a finance company with the business units Foreign Trade Finance, Proprietary Trading and M&A. The industry focus is on the food, beverages, pharmaceutical and healthcare sectors. As a specialist in foreign trade financing with a regional focus on the Middle East, Europe and Central Asia, we offer our clients customised product solutions - based on many years of experience, a strong network and comprehensive compliance expertise. M&A activities have also been an integral part of DF Group's business model since 2024.

Contact DF Deutsche Forfait AG

Guido Janzen
Director Investor Relations
Gustav-Heinemann-Ufer 56, 50968 Cologne
T +49 221 97376-61

E investor.relations@dfag.de
www.dfag.de